Making Cancer Curable: Advancing Immunotherapy
BioCanRx is spearheading efforts to make all cancers treatable through innovative immunotherapies.
As Canada’s leading immunotherapy network, BioCanRx collaborates with industry, academia, charities, and government agencies to promote translational research and develop cutting-edge treatments. Their goal is to ensure that Canadian patients have access to these therapies via clinical trials.
Despite the Canadian government investing approximately C$0.5 billion annually in cancer research, only a small portion is allocated to translational work. BioCanRx addresses this funding gap by supporting early-stage research, from proof-of-concept studies to animal models. This support is crucial for translating promising therapeutic approaches into clinically viable development programs. Since its inception in 2015, BioCanRx has been instrumental in nearly half of the clinical trials for Canadian immunotherapies based on homegrown innovations. View the full article here.
This article was produced and sponsored by BioCanRx. If you want to feature with our leading immunotherapy network to accelerate innovative research, get in touch to find out more about our sponsorship opportunities.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
